Vertex Pharmaceuticals Incorpor
VRTX
Jodie read · what matters now
Revenue increased 7.8% versus the comparable filing period.
The story is only the start. Jodie keeps watching the filing evidence, the companies connected to VRTX, and whether its market group begins moving.
Latest filing assessment · baseline
Fundamentals strengthened in the latest filing
10-Q filed 2026-05-05 against the comparable filing from 2025-05-06.
What improved
- Revenue increased 7.8% versus the comparable filing period.
- Operating margin improved 15.4 percentage points.
- Net income increased 59.6% versus the comparable filing period.
What weakened
No thresholded deterioration was identified.
Filing receipts
“Cash Flows Three Months Ended March 31, 2026 2025 (in millions) Net cash provided by (used in): Operating activities $ 1,428.1 $ 818.9 Investing activities $ (431.9) $ (55.8) Financing activities $ (538.8) $ (680.4) Operating Activities Cash provided by operating activities increased to $1.4 billion in the first quarter of 2026 , as compared to $818.9 million in the first quarter of 2025 , primarily due to the timing of tax payments and increased accounts receivable during the first quarter of 2025 resulting from our product launches .”
“39.8 7% Working Capital As of March 31, 2026 , total working capital was $7.8 billion , which represented an increase of $509.9 million , or 7% , compared to December 31, 2025 , primarily due to increased cash, cash equivalents and marketable securities resulting from our growing portfolio of products, partially offset by tax accruals and payments.”
“Cash Our total cash, cash equivalents and marketable securities increased to $13.0 billion as of March 31, 2026 as compared to $12.3 billion as of December 31, 2025 , primarily due to cash flows provided by our operating activities partially offset by repurchases of our common stock.”
Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.
Who this business touches
The relationships behind VRTX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Filing peers
Companies whose filings use similar operating language.
You can see the shape of the network here. Pro opens 7 more links, the original filing receipts, and alerts when connected names begin moving. See Pro →
What is moving around it
Live connections
VRTX is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Theme membership history
No durable theme membership has been observed for this name yet.